Why the study?
Does soluble Ninjurin-1 (sNinj1) ameliorate atherosclerosis by regulating macrophage inflammation and monocyte recruitment?
Does soluble Ninjurin-1 (sNinj1) ameliorate atherosclerosis by regulating macrophage inflammation and monocyte recruitment?
Soluble Ninjurin-1 (sNinj1) acts as an atheroprotective protein by reducing macrophage inflammation and monocyte recruitment, highlighting a potential novel pathway in atherosclerosis.
Caution against clinical translation; leaves open sNinj1 as atheroprotective target pending human studies.
Ninj1 is a novel matrix metalloproteinase 9 substrate in macrophages, and sNinj1 is a secreted atheroprotective protein that regulates macrophage inflammation and monocyte recruitment in atherosclerosis. Moreover, sNinj1-mediated anti-inflammatory effects are conserved in human macrophages and likely contribute to human atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Jeon et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: